Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.37
TFX's Cash to Debt is ranked lower than
81% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 3.05 vs. TFX: 0.37 )
Ranked among companies with meaningful Cash to Debt only.
TFX' s Cash to Debt Range Over the Past 10 Years
Min: 0.06  Med: 0.22 Max: 0.93
Current: 0.37
0.06
0.93
Equity to Asset 0.52
TFX's Equity to Asset is ranked lower than
67% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.66 vs. TFX: 0.52 )
Ranked among companies with meaningful Equity to Asset only.
TFX' s Equity to Asset Range Over the Past 10 Years
Min: 0.32  Med: 0.48 Max: 0.53
Current: 0.52
0.32
0.53
Interest Coverage 5.49
TFX's Interest Coverage is ranked lower than
82% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 50.91 vs. TFX: 5.49 )
Ranked among companies with meaningful Interest Coverage only.
TFX' s Interest Coverage Range Over the Past 10 Years
Min: 2.57  Med: 3.42 Max: 6.06
Current: 5.49
2.57
6.06
F-Score: 7
Z-Score: 3.05
M-Score: -2.58
WACC vs ROIC
7.80%
11.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 17.60
TFX's Operating margin (%) is ranked higher than
86% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 2.36 vs. TFX: 17.60 )
Ranked among companies with meaningful Operating margin (%) only.
TFX' s Operating margin (%) Range Over the Past 10 Years
Min: -6.28  Med: 13.90 Max: 15.48
Current: 17.6
-6.28
15.48
Net-margin (%) 14.25
TFX's Net-margin (%) is ranked higher than
85% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 0.77 vs. TFX: 14.25 )
Ranked among companies with meaningful Net-margin (%) only.
TFX' s Net-margin (%) Range Over the Past 10 Years
Min: -12.25  Med: 8.23 Max: 21.15
Current: 14.25
-12.25
21.15
ROE (%) 13.15
TFX's ROE (%) is ranked higher than
78% of the 297 Companies
in the Global Medical Devices industry.

( Industry Median: 0.98 vs. TFX: 13.15 )
Ranked among companies with meaningful ROE (%) only.
TFX' s ROE (%) Range Over the Past 10 Years
Min: -10.11  Med: 11.80 Max: 21.44
Current: 13.15
-10.11
21.44
ROA (%) 6.55
TFX's ROA (%) is ranked higher than
73% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: -0.34 vs. TFX: 6.55 )
Ranked among companies with meaningful ROA (%) only.
TFX' s ROA (%) Range Over the Past 10 Years
Min: -4.96  Med: 4.99 Max: 8.55
Current: 6.55
-4.96
8.55
ROC (Joel Greenblatt) (%) 38.56
TFX's ROC (Joel Greenblatt) (%) is ranked higher than
85% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. TFX: 38.56 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
TFX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -13.28  Med: 30.12 Max: 44.46
Current: 38.56
-13.28
44.46
Revenue Growth (3Y)(%) 1.90
TFX's Revenue Growth (3Y)(%) is ranked lower than
57% of the 231 Companies
in the Global Medical Devices industry.

( Industry Median: 3.70 vs. TFX: 1.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
TFX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -14.9  Med: 3.45 Max: 17.3
Current: 1.9
-14.9
17.3
EBITDA Growth (3Y)(%) 4.60
TFX's EBITDA Growth (3Y)(%) is ranked higher than
53% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. TFX: 4.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
TFX' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -13.1  Med: 5.40 Max: 15.3
Current: 4.6
-13.1
15.3
EPS Growth (3Y)(%) 11.50
TFX's EPS Growth (3Y)(%) is ranked higher than
61% of the 202 Companies
in the Global Medical Devices industry.

( Industry Median: 3.50 vs. TFX: 11.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
TFX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -16.1  Med: 3.80 Max: 16.1
Current: 11.5
-16.1
16.1
» TFX's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

TFX Guru Trades in Q2 2015

Third Avenue Management 56,069 sh (unchged)
John Keeley 3,170 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 330,700 sh (-4.12%)
Murray Stahl 5,082 sh (-16.36%)
Joel Greenblatt 160,323 sh (-37.72%)
Steven Cohen 111,100 sh (-41.61%)
Jim Simons 105,697 sh (-76.52%)
» More
Q3 2015

TFX Guru Trades in Q3 2015

John Keeley 3,170 sh (unchged)
Third Avenue Management 56,069 sh (unchged)
Jim Simons Sold Out
Murray Stahl 5,017 sh (-1.28%)
Joel Greenblatt 132,561 sh (-17.32%)
Chuck Royce 207,700 sh (-37.19%)
Steven Cohen 23,900 sh (-78.49%)
» More
Q4 2015

TFX Guru Trades in Q4 2015

Jim Simons 40,600 sh (New)
John Keeley 3,170 sh (unchged)
Jerome Dodson Sold Out
Steven Cohen Sold Out
Murray Stahl 4,942 sh (-1.49%)
Chuck Royce 181,800 sh (-12.47%)
Third Avenue Management 45,957 sh (-18.03%)
Joel Greenblatt 85,071 sh (-35.83%)
» More
Q1 2016

TFX Guru Trades in Q1 2016

George Soros 5,800 sh (New)
Paul Tudor Jones 8,620 sh (New)
Jim Simons 154,100 sh (+279.56%)
John Keeley 5,255 sh (+65.77%)
Chuck Royce 181,800 sh (unchged)
Murray Stahl 4,792 sh (-3.04%)
Third Avenue Management 38,457 sh (-16.32%)
Joel Greenblatt 25,631 sh (-69.87%)
» More
» Details

Insider Trades

Latest Guru Trades with TFX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices
Compare:NYSE:MDT, NYSE:ABT, NYSE:SYK, NYSE:BSX, NAS:ISRG, NYSE:ZBH » details
Traded in other countries:TBH.Germany,
Teleflex Inc designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications.

Teleflex Inc is a Delaware Corporation incorporated in 1943. The Company is a provider of medical technology products that provides clinical benefits, improve patient and provider safety and reduce total procedural costs. It designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It sells its products to hospitals and healthcare providers in more than 150 countries through a combination of its direct sales force and distributors. The Company manufactures its products at 27 manufacturing sites, with major manufacturing operations located in the Czech Republic, Germany, Malaysia, Mexico and the United States. It provides a broad-based platform of products, which it categorizes into four groups namely Critical Care, Surgical Care, Cardiac Care and OEM and Development Services. It is a provider of specialty products for critical care, which is predominantly comprised of single-use products. The large majority of sales for single-use products are made to the hospital/healthcare provider market, with a smaller percentage sold to alternate sites. The Company's surgical products include ligation and closure products, including appliers, clips and sutures used in a variety of surgical procedures; access ports used in minimally invasive surgical procedures, including robotic surgery; and fluid management products used for chest drainage. The Company's surgical products also include hand-held instruments for general and specialty surgical procedures. It markets surgical products under the Deknatel, Pleur-evac, Pilling, Taut and Weck brand names. Products in Cardiac Care category include diagnostic catheters and capital equipment. The Company's diagnostic catheters include thermodilution and wedge pressure catheters; specialized angiographic catheters, such as Berman and Reverse Berman catheters; therapeutic delivery catheters, such as temporary pacing catheters; sheaths for femoral and trans-radial aortic access used in diagnostic and therapeutic procedures; and intra-aortic balloon, or IAB, catheters. Capital equipment includes its intra-aortic balloon pump, or IABP, consoles. IABP products are used to augment oxygen delivery to the cardiac muscle and reduce the oxygen demand after cardiac surgery, serious heart attack or interventional procedures. The IAB and IABP product lines feature the AutoCAT 2 WAVE console and the FiberOptix catheter, which together utilize fiber optic technology for arterial pressure signal acquisition and enable the patented WAVE timing algorithm to support the broadest range of patient heart rhythms, including severely arrhythmic patients. The Company's OEM division, which includes the TFX OEM(r) and Deknatel(r) OEM nameplates, provides custom-engineered extrusions, diagnostic and interventional catheters, sheath/dilator sets (introducers) and kits, sutures, perfo

Ratios

vs
industry
vs
history
P/E(ttm) 30.13
TFX's P/E(ttm) is ranked lower than
58% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 25.75 vs. TFX: 30.13 )
Ranked among companies with meaningful P/E(ttm) only.
TFX' s P/E(ttm) Range Over the Past 10 Years
Min: 4.99  Med: 18.95 Max: 232.99
Current: 30.13
4.99
232.99
Forward P/E 19.38
TFX's Forward P/E is ranked higher than
54% of the 54 Companies
in the Global Medical Devices industry.

( Industry Median: 20.75 vs. TFX: 19.38 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.20
TFX's PE(NRI) is ranked lower than
60% of the 167 Companies
in the Global Medical Devices industry.

( Industry Median: 26.67 vs. TFX: 31.20 )
Ranked among companies with meaningful PE(NRI) only.
TFX' s PE(NRI) Range Over the Past 10 Years
Min: 14.01  Med: 28.55 Max: 74.07
Current: 31.2
14.01
74.07
Price/Owner Earnings (ttm) 27.60
TFX's Price/Owner Earnings (ttm) is ranked higher than
55% of the 113 Companies
in the Global Medical Devices industry.

( Industry Median: 30.78 vs. TFX: 27.60 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
TFX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.83  Med: 13.77 Max: 46.35
Current: 27.6
5.83
46.35
P/B 3.40
TFX's P/B is ranked lower than
59% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.69 vs. TFX: 3.40 )
Ranked among companies with meaningful P/B only.
TFX' s P/B Range Over the Past 10 Years
Min: 1.04  Med: 1.85 Max: 3.41
Current: 3.4
1.04
3.41
P/S 4.32
TFX's P/S is ranked lower than
64% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 3.12 vs. TFX: 4.32 )
Ranked among companies with meaningful P/S only.
TFX' s P/S Range Over the Past 10 Years
Min: 0.71  Med: 1.60 Max: 4.32
Current: 4.32
0.71
4.32
PFCF 28.28
TFX's PFCF is ranked lower than
51% of the 91 Companies
in the Global Medical Devices industry.

( Industry Median: 28.14 vs. TFX: 28.28 )
Ranked among companies with meaningful PFCF only.
TFX' s PFCF Range Over the Past 10 Years
Min: 5.91  Med: 14.77 Max: 52.14
Current: 28.28
5.91
52.14
POCF 23.54
TFX's POCF is ranked lower than
60% of the 131 Companies
in the Global Medical Devices industry.

( Industry Median: 19.95 vs. TFX: 23.54 )
Ranked among companies with meaningful POCF only.
TFX' s POCF Range Over the Past 10 Years
Min: 5.22  Med: 11.90 Max: 27.23
Current: 23.54
5.22
27.23
EV-to-EBIT 24.86
TFX's EV-to-EBIT is ranked lower than
56% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.22 vs. TFX: 24.86 )
Ranked among companies with meaningful EV-to-EBIT only.
TFX' s EV-to-EBIT Range Over the Past 10 Years
Min: -40.5  Med: 16.70 Max: 27.7
Current: 24.86
-40.5
27.7
EV-to-EBITDA 18.28
TFX's EV-to-EBITDA is ranked lower than
55% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 17.06 vs. TFX: 18.28 )
Ranked among companies with meaningful EV-to-EBITDA only.
TFX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -905.4  Med: 11.30 Max: 904.3
Current: 18.28
-905.4
904.3
Shiller P/E 37.99
TFX's Shiller P/E is ranked higher than
53% of the 43 Companies
in the Global Medical Devices industry.

( Industry Median: 39.79 vs. TFX: 37.99 )
Ranked among companies with meaningful Shiller P/E only.
TFX' s Shiller P/E Range Over the Past 10 Years
Min: 10.89  Med: 20.11 Max: 38.27
Current: 37.99
10.89
38.27
Current Ratio 1.61
TFX's Current Ratio is ranked lower than
77% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. TFX: 1.61 )
Ranked among companies with meaningful Current Ratio only.
TFX' s Current Ratio Range Over the Past 10 Years
Min: 1.46  Med: 1.99 Max: 5.2
Current: 1.61
1.46
5.2
Quick Ratio 1.11
TFX's Quick Ratio is ranked lower than
77% of the 317 Companies
in the Global Medical Devices industry.

( Industry Median: 2.10 vs. TFX: 1.11 )
Ranked among companies with meaningful Quick Ratio only.
TFX' s Quick Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.26 Max: 4.01
Current: 1.11
0.86
4.01
Days Inventory 144.68
TFX's Days Inventory is ranked lower than
55% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. TFX: 144.68 )
Ranked among companies with meaningful Days Inventory only.
TFX' s Days Inventory Range Over the Past 10 Years
Min: 79.93  Med: 129.96 Max: 143.59
Current: 144.68
79.93
143.59
Days Sales Outstanding 55.54
TFX's Days Sales Outstanding is ranked higher than
68% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 69.05 vs. TFX: 55.54 )
Ranked among companies with meaningful Days Sales Outstanding only.
TFX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.03  Med: 60.37 Max: 70.12
Current: 55.54
47.03
70.12
Days Payable 31.18
TFX's Days Payable is ranked lower than
82% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 62.25 vs. TFX: 31.18 )
Ranked among companies with meaningful Days Payable only.
TFX' s Days Payable Range Over the Past 10 Years
Min: 26.07  Med: 33.20 Max: 41.78
Current: 31.18
26.07
41.78

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.85
TFX's Dividend Yield is ranked lower than
68% of the 170 Companies
in the Global Medical Devices industry.

( Industry Median: 1.73 vs. TFX: 0.85 )
Ranked among companies with meaningful Dividend Yield only.
TFX' s Dividend Yield Range Over the Past 10 Years
Min: 0.84  Med: 1.82 Max: 3.48
Current: 0.85
0.84
3.48
Dividend Payout 0.27
TFX's Dividend Payout is ranked higher than
67% of the 116 Companies
in the Global Medical Devices industry.

( Industry Median: 0.37 vs. TFX: 0.27 )
Ranked among companies with meaningful Dividend Payout only.
TFX' s Dividend Payout Range Over the Past 10 Years
Min: 0.17  Med: 0.30 Max: 1.26
Current: 0.27
0.17
1.26
Forward Dividend Yield 0.86
TFX's Forward Dividend Yield is ranked lower than
75% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 1.65 vs. TFX: 0.86 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 0.85
TFX's Yield on cost (5-Year) is ranked lower than
74% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 1.83 vs. TFX: 0.85 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
TFX' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0.84  Med: 1.82 Max: 3.48
Current: 0.85
0.84
3.48
3-Year Average Share Buyback Ratio -2.10
TFX's 3-Year Average Share Buyback Ratio is ranked higher than
57% of the 200 Companies
in the Global Medical Devices industry.

( Industry Median: -3.60 vs. TFX: -2.10 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
TFX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -2.1  Med: -1.00 Max: 0.8
Current: -2.1
-2.1
0.8

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 2.40
TFX's Price/Projected FCF is ranked lower than
56% of the 121 Companies
in the Global Medical Devices industry.

( Industry Median: 2.07 vs. TFX: 2.40 )
Ranked among companies with meaningful Price/Projected FCF only.
TFX' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.47  Med: 1.12 Max: 2.88
Current: 2.4
0.47
2.88
Price/Median PS Value 2.68
TFX's Price/Median PS Value is ranked lower than
92% of the 265 Companies
in the Global Medical Devices industry.

( Industry Median: 1.01 vs. TFX: 2.68 )
Ranked among companies with meaningful Price/Median PS Value only.
TFX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.44  Med: 0.72 Max: 2.63
Current: 2.68
0.44
2.63
Earnings Yield (Greenblatt) (%) 3.96
TFX's Earnings Yield (Greenblatt) (%) is ranked higher than
71% of the 318 Companies
in the Global Medical Devices industry.

( Industry Median: 0.80 vs. TFX: 3.96 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
TFX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.6  Med: 5.80 Max: 10.3
Current: 3.96
3.6
10.3
Forward Rate of Return (Yacktman) (%) 4.01
TFX's Forward Rate of Return (Yacktman) (%) is ranked lower than
60% of the 115 Companies
in the Global Medical Devices industry.

( Industry Median: 6.77 vs. TFX: 4.01 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
TFX' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: 3.1  Med: 6.65 Max: 19.1
Current: 4.01
3.1
19.1

More Statistics

Revenue (TTM) (Mil) $1,805
EPS (TTM) $ 5.31
Beta0.86
Short Percentage of Float4.91%
52-Week Range $122.13 - 163.33
Shares Outstanding (Mil)43.60

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 1,883 1,999 2,143
EPS ($) 7.08 8.18 7.87
EPS without NRI ($) 7.08 8.18 7.87
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for TFX

Headlines

Articles On GuruFocus.com
Teleflex Declares Its Quarter Four Results Feb 24 2015 
Third Avenue Management Update Aug 31 2013 
My Dividend Portfolio Looks Much Better than I Expected Jun 03 2013 
Teleflex Incorporated: Successful Transition into Pure-Play Medical Device Manufacturer Nov 19 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
Teleflex: High Upside Potential This Year Mar 27 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Third Avenue Management Buys Lowes, Teleflex, American Eagle Outfitters, Tellabs, Sells Pharmaceutic Nov 17 2011 
Teleflex Inc. Reports Operating Results (10-Q) Oct 27 2010 
Teleflex Inc. Reports Operating Results (10-Q) Jul 23 2010 

More From Other Websites
Teleflex to Showcase Key Anaesthesia Products at Euroanaesthesia 2016 ("ESA") in London May 24 2016
Teleflex to Showcase Key Anaesthesia Products at Euroanaesthesia 2016 ("ESA") in London May 24 2016
Teleflex to Showcase Key Anaesthesia Products at Euroanaesthesia 2016 ("ESA") in London May 24 2016
Teleflex to Present at the 53rd European Renal, Dialysis and Transplant Congress (ERA-EDTA) May 18 2016
Teleflex to Present at the 53rd European Renal, Dialysis and Transplant Congress (ERA-EDTA) May 18 2016
TELEFLEX INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct... May 16 2016
IHI Remains Stable in a Sluggish Market May 13 2016
Layoff mixup: Only 84 workers to lose jobs in near term, not 456, company states May 13 2016
TELEFLEX INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 12 2016
Teleflex Incorporated Announces Pricing of $400 Million Senior Notes Offering May 11 2016
Teleflex Incorporated Announces Pricing of $400 Million Senior Notes Offering May 11 2016
Teleflex Incorporated -- Moody's rates Teleflex notes Ba3; stable outlook May 11 2016
Teleflex Incorporated Announces Public Offering of $400 Million of Senior Notes May 11 2016
TELEFLEX INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 05 2016
ETF’s with exposure to Teleflex, Inc. : May 4, 2016 May 04 2016
TELEFLEX INC Financials May 04 2016
Teleflex, Inc. :TFX-US: Earnings Analysis: Q1, 2016 By the Numbers May 03 2016
Teleflex to Present at the 2nd Congress of Society of Endometriosis and Uterine Disorders (SEUD) May 03 2016
Teleflex to Present at the 2nd Congress of Society of Endometriosis and Uterine Disorders (SEUD) May 03 2016
Teleflex Announces Quarterly Dividend May 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)